Blum, Kenneth
Simpatico, Thomas
Febo, Marcelo
Rodriquez, Chris
Dushaj, Kristina
Li, Mona
Braverman, Eric R.
Demetrovics, Zsolt
Oscar-Berman, Marlene
Badgaiyan, Rajendra D.
Funding for this research was provided by:
National Institutes of Health (1R01NS073884, 1R21MH073624, R01DA019946, R21DA038009)
National Institute on Alcohol Abuse and Alcoholism (RO1-AA07112)
National Institute on Alcohol Abuse and Alcoholism (K05-AA00219)
U.S. Department of Veterans Affairs
Life Extension Foundation
Article History
Received: 25 November 2015
Accepted: 10 May 2016
First Online: 31 May 2016
Compliance with Ethical Standards
:
: Kenneth Blum holds the US and Foreign nutrigenomic patents to treat Reward Deficiency Syndrome (RDS) with dopaminergic agonists. Dr. Blum is a member of the scientific advisory board of Dominion Diagnostics, LLC.
: KB wrote the basic manuscript. TS is a psychiatrist and musician who provided the impetus and design for the hypothesis. KD reviewed and developed the second draft of the manuscript. ZD, MOB added important comments and clinical interpretations. CR provided information related to the practice of music from a perspective of a musician. ERB, RDB and ML provided manuscript edits and comments concerning clinical applications and psychiatry.
: This work was supported by the National Institutes of Health grants 1R01NS073884 and 1R21MH073624, awarded to Dr. Rajendra D Badgaiyan. Dr. Marcelo Febo is the recipient of R01DA019946 and R21DA038009. The writing of this paper was supported in part by funds from the National Institutes of Health, NIAAA (RO1-AA07112 and K05-AA00219), and the Medical Research Service of the US Department of Veterans Affairs (MOB). KB and ERB are the recipients of a grant to PATH FOUNDATION NY, by Life Extension Foundation, Ft/Lauderdale, Florida.